Acute exposure to lead increases myocardial contractility independent of hypertension development

Brazilian Journal of Medical and Biological Research

Volumn 46, Issue 2, 2013, Pages 178-185

  Fioresi, M ^a   Furieri, L B ^a   Simoes M R ^a   Ribeiro Junior, R F ^a   Meira, E F ^a   Fernandes, A A ^a   Stefanon, I ^a   Vassallo, D V ^a,b  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria   (Brazil)

Author keywords

Lead; Myocardial contractility; Ventricular pressure

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ISOPRENALINE; LEAD ACETATE; MYOSIN ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE; MYOSIN; ORGANOMETALLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART MUSCLE CONTRACTILITY; HEART PAPILLARY MUSCLE; HEART VENTRICLE PRESSURE; HEMODYNAMIC PARAMETERS; HYPERTENSION; LEAD POISONING; MALE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE SYMPATHETIC NERVE ACTIVITY; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; HEART CONTRACTION; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ENZYME ACTIVATION; HYPERTENSION; MALE; MYOCARDIAL CONTRACTION; MYOSINS; ORGANOMETALLIC COMPOUNDS; RATS, WISTAR;

EID: 84875655501     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20122190     Document Type: Article

References (40)

1. Pabello NG, Bolivar VJ. Young brains on lead: adult neurological consequences? Toxicol Sci 2005; 86: 211-213, doi: 10.1093/toxsci/kfi221.
2. Patrick L. Lead toxicity part II: the role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. Altern Med Rev 2006; 11: 114-127.
3. Prozialeck WC, Edwards JR, Nebert DW, Woods JM, Barchowsky A, Atchison WD. The vascular system as a target of metal toxicity. Toxicol Sci 2008; 102: 207-218, doi: 10.1093/toxsci/kfm263.
4. Roncal C, Mu W, Reungjui S, Kim KM, Henderson GN, Ouyang X, et al. Lead, at low levels, accelerates arteriolo-pathy and tubulointerstitial injury in chronic kidney disease. Am J Physiol Renal Physiol 2007; 293: F1391-F1396, doi: 10.1152/ajprenal.00216.2007.
5. Lustberg M, Silbergeld E. Blood lead levels and mortality. Arch Intern Med 2002; 162: 2443-2449, doi: 10.1001/ archinte.162.21.2443.
6. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease - a systematic review. Environ Health Perspect 2007; 115: 472-482, doi: 10.1289/ehp.9785.
7. Hertz-Picciotto I, Croft J. Review of the relation between blood lead and blood pressure. Epidemiol Rev 1993; 15: 352-373.
8. Schober SE, Mirel LB, Graubard BI, Brody DJ, Flegal KM. Blood lead levels and death from all causes, cardiovascular disease, and cancer: results from the NHANES III mortality study. Environ Health Perspect 2006; 114: 1538-1541.
9. Staessen JA, Bulpitt CJ, Fagard R, Lauwerys RR, Roels H, Thijs L, et al. Hypertension caused by low-level lead exposure: myth or fact? J Cardiovasc Risk 1994; 1: 87-97, doi: 10.1097/00043798-199406000-00014.
10. Boscolo P, Carmignani M. Neurohumoral blood pressure regulation in lead exposure. Environ Health Perspect 1988; 78: 101-106, doi: 10.1289/ehp.8878101.
11. Carmignani M, Volpe AR, Boscolo P, Qiao N, Di Gioacchino M, Grilli A, et al. Catcholamine and nitric oxide systems as targets of chronic lead exposure in inducing selective functional impairment. Life Sci 2000; 68: 401-415, doi: 10.1016/S0024-3205(00)00954-1.
12. Tsao DA, Yu HS, Cheng JT, Ho CK, Chang HR. The change of beta-adrenergic system in lead-induced hypertension. Toxicol Appl Pharmacol 2000; 164: 127-133, doi: 10.1006/ taap.1999.8871.
13. Hejtmancik MR Jr., Williams BJ. Effect of chronic lead exposure on the direct and indirect components of the cardiac response to norepinephrine. Toxicol Appl Pharmacol 1979; 51: 239-245, doi: 10.1016/0041-008X(79)90466-6.
14. Carmignani M, Boscolo P, Poma A, Volpe AR. Kininergic system and arterial hypertension following chronic exposure to inorganic lead. Immunopharmacology 1999; 44: 105-110, doi: 10.1016/S0162-3109(99)00115-0.
15. Prentice RC, Kopp SJ. Cardiotoxicity of lead at various perfusate calcium concentrations: functional and metabolic responses of the perfused rat heart. Toxicol Appl Pharmacol 1985; 81: 491-501, doi: 10.1016/0041-008X(85)90420-X.
16. ++ channels requires treatment with heavy metal antidotes. J Pharmacol Exp Ther 1997; 282: 172-180.
17. Vassallo DV, Lebarch EC, Moreira CM, Wiggers GA, Stefanon I. Lead reduces tension development and the myosin ATPase activity of the rat right ventricular myocardium. Braz J Med Biol Res 2008; 41: 789-795, doi: 10.1590/ S0100-879X2008000900008.
18. 2+-stimulated ATPase activity. Anal Biochem 1986; 157: 375-380, doi: 10.1016/0003-2697(86)90640-8.
19. Klotz C, Aumont MC, Berson G, Leger JJ, Preteseille M, Swynghedauw B. Cardiac myosin: preparation, ATPase in chronic heart hypertrophy. Recent Adv Stud Cardiac Struct Metab 1975; 5: 263-271.
20. Cappelli V, Bottinelli R, Poggesi C, Moggio R, Reggiani C. Shortening velocity and myosin and myofibrillar ATPase activity related to myosin isoenzyme composition during postnatal development in rat myocardium. Circ Res 1989; 65: 446-457, doi: 10.1161/01.RES.65.2.446.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254, doi: 10.1016/0003-2697(76)90527-3.
22. + ATPase activity are reduced early and late after myocardial infarction in rats. Braz J Med Biol Res 2009; 42: 902-911, doi: 10.1590/S0100-879X2009005000015.
23. Glitsch HG. Electrophysiology of the sodium-potassium-ATPase in cardiac cells. Physiol Rev 2001; 81: 1791-1826.
24. Gelband H, Myerburg RJ, Hoffman BF, Bassett AL. Acetylcholine-induced reversal of canine and feline atrial myocardial depression during stretch, cardiac failure, and drug toxicity. Circ Res 1975; 37: 542-549, doi: 10.1161/ 01.RES.37.5.542.
25. Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation 2006; 114: 1388-1394, doi: 10.1161/CIRCULATIONAHA.106.628321.
26. Weiler E, Khalil-Manesh F, Gonick HC. Effects of lead and a low-molecular-weight endogenous plasma inhibitor on the kinetics of sodium-potassium-activated adenosine tripho-sphatase and potassium-activated p-nitrophenylphospha-tase. Clin Sci 1990; 79: 185-192.
27. Gonick HC, Ding Y, Bondy SC, Ni Z, Vaziri ND. Lead-induced hypertension: interplay of nitric oxide and reactive oxygen species. Hypertension 1997; 30: 1487-1492, doi: 10.1161/01.HYP.30.6.1487.
28. Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation 2004; 109: 3196-3201, doi: 10.1161/01.CIR.0000130848. 18636.B2.
29. Vaziri ND, Ding Y, Ni Z, Gonick HC. Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy. Kidney Int 1997; 52: 1042-1046, doi: 10.1038/ki.1997.426.
30. Grizzo LT, Cordellini S. Perinatal lead exposure affects nitric oxide and cyclooxygenase pathways in aorta of weaned rats. Toxicol Sci 2008; 103: 207-214, doi: 10.1093/toxsci/ kfn018.
31. Khalil-Manesh F, Gonick HC, Weiler EW, Prins B, Weber MA, Purdy RE. Lead-induced hypertension: possible role of endothelial factors. Am J Hypertens 1993; 6: 723-729.
32. Farmand F, Ehdaie A, Roberts CK, Sindhu RK. Lead-induced dysregulation of superoxide dismutases, catalase, glutathione peroxidase, and guanylate cyclase. Environ Res 2005; 98: 33-39, doi: 10.1016/j.envres.2004.05.016.
33. Ni Z, Hou S, Barton CH, Vaziri ND. Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. Kidney Int 2004; 66: 2329-2336, doi: 10.1111/j.1523-1755.2004.66032.x.
34. Vaziri ND, Ding Y, Ni Z. Compensatory up-regulation of nitric-oxide synthase isoforms in lead-induced hypertension; reversal by a superoxide dismutase-mimetic drug. J Pharmacol Exp Ther 2001; 298: 679-685.
35. Simoes MR, Ribeiro Junior RF, Vescovi MV, de Jesus HC, Padilha AS, Stefanon I, et al. Acute lead exposure increases arterial pressure: role of the renin-angiotensin system. PLoS One 2011; 6: e18730, doi: 10.1371/journal.pone.0018730.
36. Mill JG, Vassallo DV, Leite CM. Mechanisms underlying the genesis of post-rest contractions in cardiac muscle. Braz J Med Biol Res 1992; 25: 399-408.
37. Endoh M, Hashimoto K. Pharmacological evidence of autonomic nerve activities in canine papillary muscle. Am J Physiol 1970; 218: 1459-1463.
38. Winegrad S, Weisberg A, Lin LE, McClellan G. Adrenergic regulation of myosin adenosine triphosphatase activity. Circ Res 1986; 58: 83-95, doi: 10.1161/01.RES.58.1.83.
39. +-ATPase alpha2-isoform regulates cardiac contractility in rat cardiomyocytes. Cardiovasc Res 2007; 75: 109-117, doi: 10.1016/j.cardiores.2007.03.017.
40. Zimmer HG, Millar HD. Technology and application of ultraminiature catheter pressure transducers. Can J Cardiol 1998; 14: 1259-1266.